Psychological MedicineNeurosciencePeer-reviewed journal article
Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of First Episode Psychosis patients and controls
Musa Basseer SamiiD, Diego QuattroneiD, Laura FerraroiD, Giada TripoliiD, Caterina La CasciaiD, Charlotte E. Gayer-AndersoniD, Jean‐Paul SelteniD, Celso ArangoiD, Miquel BernardoiD, Ilaria TarriconeiD, Andrea TortelliiD, Giusy Gatto, Simona del Peschio, Cristina Marta Del‐BeniD, Bart P. F. RutteniD, Peter Brian JonesiD, Jim van OsiD, Lieuwe de HaaniD, Craig MorganiD, Cathryn M. LewisiD, Sagnik BhattacharyyaiD, Tom P. FreemaniD, Michael T. LynskeyiD, Robin M. MurrayiD, Marta Di FortiiD
Abstract
AimsFirst Episode Psychosis (FEP) patients who use cannabis experience more frequent psychotic and euphoric intoxication experiences compared to controls. It is not clear whether this is consequent to patients being more vulnerable to the effects of cannabis use or to their heavier pattern of use. We aimed to determine whether extent of use predicted psychotic-like and euphoric intoxication experiences in FEP patients and controls and whether this differs between groups. MethodsWe analysed data on lifetime cannabis using patients (n=655) and controls (n=654) across 15 sites from six countries in the EU-GEI study (2010-2015). We used multiple regression to model predictors of cannabis-induced experiences and to determine if there was an interaction between caseness and extent of use. ResultsCaseness, frequency of cannabis use and money spent on cannabis predicted psychotic-like and euphoric experiences, independent of other experiences (p[≤]0.001). For psychotic-like experiences there was a significant interaction for caseness x frequency of use (p0.5). Conclusions and RelevanceFEP patients are particularly sensitive to increased psychotic-like, but not euphoric experiences, at higher frequency and amount of cannabis use compared to controls. This suggests a specific psychotomimetic response in patients related particularly to heavy cannabis use.
- Citations
- 11
- FWCI
- 1.50
- Field percentile
- top 22%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cannabis-associated symptom profiles in patients with first episode psychosis and population controls
Diego Quattrone, Laura Ferraro, … Marta Di Forti·bioRxiv·Mar 16, 2019
- Cannabis Use and Glutamate across the Psychosis Spectrum: In Vivo Evidence from 7T Proton Magnetic Resonance Spectroscopy
David R. Roalf, Tyler M. Moore, … James Cobb Scott·Molecular PsychiatryPeer-reviewed·Jun 27, 2026
- The independent and combined influence of schizophrenia polygenic risk score and heavy cannabis use on risk for psychotic disorder: A case-control analysis from the EUGEI study.
Marta Di Forti, Beatrice Wu-Choi, … EU-GEI WP2 Group·bioRxiv·Nov 16, 2019
- Converging effects of cannabis and psychosis on the dopamine system: A longitudinal neuromelanin-sensitive MRI study in cannabis use disorder and first episode schizophrenia.
Jessica Ahrens, Sabrina D. Ford, … Lena K. Palaniyappan·bioRxiv·Sep 12, 2024
- Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis
Alex M. Dickens, Faith Borgan, … Matej Orešič·SchizophreniaPeer-reviewed·Aug 26, 2020
- Microscopic Motor Alterations in Psychosis and Chronic Cannabis Use
Filippo Pasqualitto, Alice Tomassini, … Alessandro D’Ausilio·bioRxiv·Jun 30, 2026